A combination of two FDA-approved drugs, already approved for fighting other bacterial infections, shows potential for treating extensively drug resistant tuberculosis (XDR-TB), the most deadly form of the infection. This finding is reported by scientists from Albert Einstein College of Medicine of Yeshiva University in the February 27 issue of Science.